| Gene symbol | VEGFC | Synonyms | Flt4-L, LMPH1D, LMPHM4, VRP | Type of gene | protein-coding |
| Chromosome | 4 | Map location | 4q34.3 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | vascular endothelial growth factor C | ||||
| GTO ID | GTC2896 |
| Trial ID | NCT05197270 |
| Disease | Age-Related Macular Degeneration |
| Altered gene | VEGFC |
| Therapeutic/Target gene | Target gene|Therapeutic gene |
| Therapy | miRNA|mRNA |
| Treatment | 4D-150 |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration |
| Year | 2021 |
| Country | United States|Puerto Rico |
| Company sponsor | 4D Molecular Therapeutics |
| Other ID(s) | 4D-150-C001 |
| Vector information | |||||
|
|||||
| Cohort1: 4D-150 | |||||||||
|
|||||||||
| Cohort2: Aflibercept | |||||||||
|
|||||||||